← Leaderboards
Carol A Feghali-Bostwick
University Of Pittsburgh At Pittsburgh
$17,984,586
Attributed
$20,974,264
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,974,264 · 17
By mechanism
R01$9,495,917 · 5
T32$2,397,234 · 2
R25$1,824,520 · 1
R42$1,692,846 · 1
K24$1,378,605 · 1
TL1$1,356,315 · 1
Top collaborators
- Lynn M Schnapp4 shared
- Hal S Padgett3 shared
- Richard A Steinman2 shared
- Peggi M Angel1 shared
- Erica L Herzog1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Andrew F. Stewart$27,613,128
- Kristen L Veraldi$624,345
- Oliver Eickelberg$4,701,908
- Robyn Therese Domsic$4,058,832
- Richard A Steinman$17,934,207
Others in their field
Top investigators on “Systemic Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- John Varga · University Of Illinois At Chicago$13,781,985
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
- Maria Trojanowska · Boston University Medical Campus$10,085,547
- Maureen Maureen Mayes · Wayne State University$9,729,622
Research focus
Systemic SclerodermaLungFibrosisSkinSclerodermaFibroblastsConnective Tissue DiseasesPulmonary FibrosisCause Of DeathPhenotypeGeneticEtiologyIn VitroOrganPathogenesisCollagenLeadProgramsAffectMediatingGenesPeptidesStructure Of Parenchyma Of LungUniversities
Grant awards (62)
Mitochondrial DNA and Sex Differences in Scleroderma-Associated ILD$1,498,380
R01 · FY2025 · HL
Peptides for the treatment of pulmonary fibrosis$464,121
R33 · FY2025 · HL · contact PI
ASCEnD - A national program of Academic Support and Coaching for Entrepreneurial Development$457,484
R25 · FY2025 · GM · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$261,076
T32 · FY2025 · HL · contact PI
CTSA Predoctoral T32 Program at the Medical University of South Carolina$237,032
T32 · FY2025 · TR · contact PI
Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc$130,189
K24 · FY2025 · AR · contact PI
Peptides for the treatment of pulmonary fibrosis$464,121
R33 · FY2024 · HL · contact PI
NRSA Training Core$463,860
TL1 · FY2024 · TR · contact PI
STEM-Coaching and Resources for Entrepreneurial Women (CREW)$457,484
R25 · FY2024 · GM · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$450,155
T32 · FY2024 · HL · contact PI
TT-036 for the treatment of scleroderma-associated pulmonary fibrosis$389,754
R41 · FY2024 · HL · contact PI
Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc$130,189
K24 · FY2024 · AR · contact PI
STEM-Coaching and Resources for Entrepreneurial Women (CREW)$457,007
R25 · FY2023 · GM · contact PI
NRSA Training Core$451,602
TL1 · FY2023 · TR · contact PI
IGF-II regulates lung fibrosis in scleroderma$373,750
R01 · FY2023 · HL · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$206,711
T32 · FY2023 · HL · contact PI
Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc$130,189
K24 · FY2023 · AR · contact PI
STEM-Coaching and Resources for Entrepreneurial Women (CREW)$452,545
R25 · FY2022 · GM · contact PI
NRSA Training Core$440,853
TL1 · FY2022 · TR · contact PI
IGF-II regulates lung fibrosis in scleroderma$373,750
R01 · FY2022 · HL · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$299,864
T32 · FY2022 · HL · contact PI
Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc$130,189
K24 · FY2022 · AR · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$383,929
T32 · FY2021 · HL · contact PI
IGF-II regulates lung fibrosis in scleroderma$373,750
R01 · FY2021 · HL · contact PI
Development of proteomic-based ECM signatures for lung fibrosis$364,870
R21 · FY2021 · AR · contact PI
Scleroderma Twin Study and analysis of Estrogen in patients with dcSSc$206,632
K24 · FY2021 · AR · contact PI
Role of pericytes in scleroderma skin and lung fibrosis$440,389
R01 · FY2020 · HL
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$378,434
T32 · FY2020 · HL · contact PI
IGF-II regulates lung fibrosis in scleroderma$373,750
R01 · FY2020 · HL · contact PI
Mechanism of Action of Anti-Fibrotic Peptide$373,750
R01 · FY2020 · HL · contact PI
Role of pericytes in scleroderma skin and lung fibrosis$522,531
R01 · FY2019 · HL
Mechanism of Action of Anti-Fibrotic Peptide$373,750
R01 · FY2019 · HL · contact PI
Pulmonary Focused Foundations in Innovation and Scholarship (PuFFInS)$180,033
T32 · FY2019 · HL · contact PI
Role of pericytes in scleroderma skin and lung fibrosis$522,531
R01 · FY2018 · HL
Mechanism of Action of Anti-Fibrotic Peptide$373,750
R01 · FY2018 · HL · contact PI
Peptide Based Therapy for Lung Fibrosis$743,057
R42 · FY2017 · HL
Role of pericytes in scleroderma skin and lung fibrosis$521,185
R01 · FY2017 · HL
Mechanism of Action of Anti-Fibrotic Peptide$373,750
R01 · FY2017 · HL · contact PI
Scleroderma Twin Study$129,866
K24 · FY2017 · AR · contact PI
Peptide Based Therapy for Lung Fibrosis$749,790
R42 · FY2016 · HL
Scleroderma Twin Study$129,866
K24 · FY2016 · AR · contact PI
Peptide Based Therapy for Lung Fibrosis$199,999
R42 · FY2015 · HL
Core C - Lung Pathology Core$138,867
P30 · FY2015 · AR · contact PI
Scleroderma Twin Study$129,866
K24 · FY2015 · AR · contact PI
Core C - Lung Pathology Core$141,024
P30 · FY2014 · AR · contact PI
Scleroderma Twin Study$131,866
K24 · FY2014 · AR · contact PI
Core C - Lung Pathology Core$137,702
P30 · FY2013 · AR · contact PI
Scleroderma Twin Study$84,381
K24 · FY2013 · AR · contact PI
Scleroderma Twin Study$45,372
K24 · FY2013 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$316,768
R01 · FY2012 · AR · contact PI
A mouse model enabling in vivo labeling of fibroblast-specific transcription duri$227,250
R21 · FY2012 · OD
Core C - Lung Pathology Core$144,949
P30 · FY2012 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$316,768
R01 · FY2011 · AR · contact PI
A mouse model enabling in vivo labeling of fibroblast-specific transcription duri$189,375
R21 · FY2011 · RR
Core C - Lung Pathology Core$166,794
P30 · FY2011 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$329,967
R01 · FY2010 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$333,300
R01 · FY2009 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$333,300
R01 · FY2008 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$306,939
R01 · FY2006 · AR · contact PI
Mediators of Fibrosis in Scleroderma Skin and Lung$358,701
R01 · FY2005 · AR
Mediators of Fibrosis in Scleroderma Skin and Lung$358,801
R01 · FY2004 · AR
Mediators of Fibrosis in Scleroderma Skin and Lung$346,357
R01 · FY2003 · AR